Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
351
datasets available to search
ShareScore release 0.9.0
Dataset results
351 results for “empagliflozin”
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
ClinicalTrials.gov study NCT04531462. IPD Sharing: YES. Countries: 1. Publications: 1.
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
ClinicalTrials.gov study NCT03485222. IPD Sharing: YES. Countries: 1. Publications: 5.
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
ClinicalTrials.gov study NCT00885118. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
ClinicalTrials.gov study NCT01210001. IPD Sharing: Not stated. Countries: 7. Publications: 4.
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT03817463. IPD Sharing: NO. Countries: 11. Publications: 1.
Protocol, case report(s), ethics approvals, informed consent, inclusion and exclusion criteria underlying: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Pharmacokinetics parameters, bioanalytical method underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover non-randomised trial
Open the record for dataset details and reuse information.
Demographic data, reporting guidelines underlying the manuscript: The effect of morning versus evening administration of Empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two way cross over, non-randomized trial
Open the record for dataset details and reuse information.
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Reno-protective Effects of Empagliflozin in High Fat Diet Induced Obesity-Related Glomerulopathy by Regulation of Gut-Kidney Axis
Open the record for dataset details and reuse information.
Multi-omics analysis reveals attenuation of cellular stress by Empagliflozin in High Glucose-treated human cardiomyocytes.
<p>Mass spectrometry raw data for the manuscript <strong>Multi-omics analysis reveals attenuation of cellular stress by Empagliflozin in High Glucose-treated human cardiomyocytes.</strong></p>
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
ClinicalTrials.gov study NCT06342141. IPD Sharing: NO. Countries: 1. Publications: 15.
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
ClinicalTrials.gov study NCT06759922. IPD Sharing: YES. Countries: 1. Publications: 14.
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
ClinicalTrials.gov study NCT04049045. IPD Sharing: Not stated. Countries: 1. Publications: 1.
EMPagliflozin After Aortic Valve Replacement
ClinicalTrials.gov study NCT06171802. IPD Sharing: NO. Countries: 1. Publications: 0.
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
ClinicalTrials.gov study NCT03202667. IPD Sharing: NO. Countries: 1. Publications: 2.
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
ClinicalTrials.gov study NCT06095492. IPD Sharing: NO. Countries: 1. Publications: 7.
Drug Interaction Study Between Dorzagliatin and Empagliflozin
ClinicalTrials.gov study NCT03790787. IPD Sharing: NO. Countries: 1. Publications: 0.
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
ClinicalTrials.gov study NCT03128528. IPD Sharing: NO. Countries: 1. Publications: 4.
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
ClinicalTrials.gov study NCT03208465. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.